Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report
Neutropenia is amongst the rare, but potentially life-threatening complications of immune checkpoint inhibitors (ICI). Awareness about this dangerous toxicity and its adequate treatment since early detection is of utmost importance. Unfortunately, there are no therapeutical guidelines to deal with n...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2022-11, Vol.14 (11), p.e31552 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | e31552 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 14 |
| creator | Miranda Baleiras, Mafalda Vasques, Carolina Pinto, Marta Miranda, Helena Martins, Ana |
| description | Neutropenia is amongst the rare, but potentially life-threatening complications of immune checkpoint inhibitors (ICI). Awareness about this dangerous toxicity and its adequate treatment since early detection is of utmost importance. Unfortunately, there are no therapeutical guidelines to deal with neutropenia specifically. The best alternative is informed extrapolations based on reported neutropenia cases and established guidelines for other immune-related adverse events. We report a case of pembrolizumab-related grade 4 neutropenia in a patient with metastatic bladder cancer. She was successfully treated with immunosuppressive and supportive measures. Further studies are required to understand the range of immune-related adverse events and to improve their management. |
| doi_str_mv | 10.7759/cureus.31552 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9754893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2756672450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-cb49ba3a93e43d62aa70ef25252bb678ff350e4ed0808a21dc5662d96d6fdec93</originalsourceid><addsrcrecordid>eNpdkc1rFTEUxUNR2lK767oE3LhwaiafMy6E56NfULSI4jJkkjs2ZSZ5JpOC_es701dLlSxyL_nl3Hs4CB3V5EQp0X6wJUHJJ6wWgu6gfVrLpmrqhr96Ue-hw5xvCSE1UZQosov2mBSciFrso_Eaxi7Fwd-X0XTVZXDFgsOrMkU_jiUAPk_GAeb4C5QpxQ0Eb7AP2OBrM3kIE_7ppxu8cncmLD8_D8Y5SHi9tOkjXs1VBvwNNjFNb9Dr3gwZDp_uA_Tj7PT7-qK6-np-uV5dVZZxOlW2421nmGkZcOYkNUYR6KmYT9dJ1fQ9EwQ4ONKQxtDaWSElda10sndgW3aAPm11N6Ubwdl5zWQGvUl-NOmPjsbrf1-Cv9G_4p1uleBNy2aBd08CKf4ukCc9-mxhGEyAWLKmap6oKBdkRt_-h97GksJsb6FaJZWSC_V-S9kUc07QPy9TE71EqbdR6scoZ_z4pYFn-G9w7AGglZug</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2759767760</pqid></control><display><type>article</type><title>Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Miranda Baleiras, Mafalda ; Vasques, Carolina ; Pinto, Marta ; Miranda, Helena ; Martins, Ana</creator><creatorcontrib>Miranda Baleiras, Mafalda ; Vasques, Carolina ; Pinto, Marta ; Miranda, Helena ; Martins, Ana</creatorcontrib><description>Neutropenia is amongst the rare, but potentially life-threatening complications of immune checkpoint inhibitors (ICI). Awareness about this dangerous toxicity and its adequate treatment since early detection is of utmost importance. Unfortunately, there are no therapeutical guidelines to deal with neutropenia specifically. The best alternative is informed extrapolations based on reported neutropenia cases and established guidelines for other immune-related adverse events. We report a case of pembrolizumab-related grade 4 neutropenia in a patient with metastatic bladder cancer. She was successfully treated with immunosuppressive and supportive measures. Further studies are required to understand the range of immune-related adverse events and to improve their management.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.31552</identifier><identifier>PMID: 36540515</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Anemia ; Bladder cancer ; Cancer therapies ; Case reports ; Chemotherapy ; Cytotoxicity ; Disease ; Immune system ; Immunotherapy ; Infections ; Monoclonal antibodies ; Mortality ; Neutropenia ; Neutrophils ; Oncology ; Patients ; Pharmacovigilance ; Steroids ; Targeted cancer therapy ; Thrombocytopenia</subject><ispartof>Curēus (Palo Alto, CA), 2022-11, Vol.14 (11), p.e31552</ispartof><rights>Copyright © 2022, Miranda Baleiras et al.</rights><rights>Copyright © 2022, Miranda Baleiras et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022, Miranda Baleiras et al. 2022 Miranda Baleiras et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-cb49ba3a93e43d62aa70ef25252bb678ff350e4ed0808a21dc5662d96d6fdec93</citedby><cites>FETCH-LOGICAL-c342t-cb49ba3a93e43d62aa70ef25252bb678ff350e4ed0808a21dc5662d96d6fdec93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754893/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754893/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36540515$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miranda Baleiras, Mafalda</creatorcontrib><creatorcontrib>Vasques, Carolina</creatorcontrib><creatorcontrib>Pinto, Marta</creatorcontrib><creatorcontrib>Miranda, Helena</creatorcontrib><creatorcontrib>Martins, Ana</creatorcontrib><title>Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Neutropenia is amongst the rare, but potentially life-threatening complications of immune checkpoint inhibitors (ICI). Awareness about this dangerous toxicity and its adequate treatment since early detection is of utmost importance. Unfortunately, there are no therapeutical guidelines to deal with neutropenia specifically. The best alternative is informed extrapolations based on reported neutropenia cases and established guidelines for other immune-related adverse events. We report a case of pembrolizumab-related grade 4 neutropenia in a patient with metastatic bladder cancer. She was successfully treated with immunosuppressive and supportive measures. Further studies are required to understand the range of immune-related adverse events and to improve their management.</description><subject>Anemia</subject><subject>Bladder cancer</subject><subject>Cancer therapies</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Cytotoxicity</subject><subject>Disease</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Infections</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Neutropenia</subject><subject>Neutrophils</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pharmacovigilance</subject><subject>Steroids</subject><subject>Targeted cancer therapy</subject><subject>Thrombocytopenia</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkc1rFTEUxUNR2lK767oE3LhwaiafMy6E56NfULSI4jJkkjs2ZSZ5JpOC_es701dLlSxyL_nl3Hs4CB3V5EQp0X6wJUHJJ6wWgu6gfVrLpmrqhr96Ue-hw5xvCSE1UZQosov2mBSciFrso_Eaxi7Fwd-X0XTVZXDFgsOrMkU_jiUAPk_GAeb4C5QpxQ0Eb7AP2OBrM3kIE_7ppxu8cncmLD8_D8Y5SHi9tOkjXs1VBvwNNjFNb9Dr3gwZDp_uA_Tj7PT7-qK6-np-uV5dVZZxOlW2421nmGkZcOYkNUYR6KmYT9dJ1fQ9EwQ4ONKQxtDaWSElda10sndgW3aAPm11N6Ubwdl5zWQGvUl-NOmPjsbrf1-Cv9G_4p1uleBNy2aBd08CKf4ukCc9-mxhGEyAWLKmap6oKBdkRt_-h97GksJsb6FaJZWSC_V-S9kUc07QPy9TE71EqbdR6scoZ_z4pYFn-G9w7AGglZug</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Miranda Baleiras, Mafalda</creator><creator>Vasques, Carolina</creator><creator>Pinto, Marta</creator><creator>Miranda, Helena</creator><creator>Martins, Ana</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221115</creationdate><title>Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report</title><author>Miranda Baleiras, Mafalda ; Vasques, Carolina ; Pinto, Marta ; Miranda, Helena ; Martins, Ana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-cb49ba3a93e43d62aa70ef25252bb678ff350e4ed0808a21dc5662d96d6fdec93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anemia</topic><topic>Bladder cancer</topic><topic>Cancer therapies</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Cytotoxicity</topic><topic>Disease</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Infections</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Neutropenia</topic><topic>Neutrophils</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pharmacovigilance</topic><topic>Steroids</topic><topic>Targeted cancer therapy</topic><topic>Thrombocytopenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miranda Baleiras, Mafalda</creatorcontrib><creatorcontrib>Vasques, Carolina</creatorcontrib><creatorcontrib>Pinto, Marta</creatorcontrib><creatorcontrib>Miranda, Helena</creatorcontrib><creatorcontrib>Martins, Ana</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miranda Baleiras, Mafalda</au><au>Vasques, Carolina</au><au>Pinto, Marta</au><au>Miranda, Helena</au><au>Martins, Ana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2022-11-15</date><risdate>2022</risdate><volume>14</volume><issue>11</issue><spage>e31552</spage><pages>e31552-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Neutropenia is amongst the rare, but potentially life-threatening complications of immune checkpoint inhibitors (ICI). Awareness about this dangerous toxicity and its adequate treatment since early detection is of utmost importance. Unfortunately, there are no therapeutical guidelines to deal with neutropenia specifically. The best alternative is informed extrapolations based on reported neutropenia cases and established guidelines for other immune-related adverse events. We report a case of pembrolizumab-related grade 4 neutropenia in a patient with metastatic bladder cancer. She was successfully treated with immunosuppressive and supportive measures. Further studies are required to understand the range of immune-related adverse events and to improve their management.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>36540515</pmid><doi>10.7759/cureus.31552</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2022-11, Vol.14 (11), p.e31552 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9754893 |
| source | PubMed Central Open Access; PubMed Central |
| subjects | Anemia Bladder cancer Cancer therapies Case reports Chemotherapy Cytotoxicity Disease Immune system Immunotherapy Infections Monoclonal antibodies Mortality Neutropenia Neutrophils Oncology Patients Pharmacovigilance Steroids Targeted cancer therapy Thrombocytopenia |
| title | Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T04%3A00%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pembrolizumab-Induced%20Autoimmune%20Grade%204%20Neutropenia%20in%20a%20Patient%20With%20Advanced%20Bladder%20Cancer:%20A%20Case%20Report&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Miranda%20Baleiras,%20Mafalda&rft.date=2022-11-15&rft.volume=14&rft.issue=11&rft.spage=e31552&rft.pages=e31552-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.31552&rft_dat=%3Cproquest_pubme%3E2756672450%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2759767760&rft_id=info:pmid/36540515&rfr_iscdi=true |